{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:18:55Z","timestamp":1777918735478,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[1997,5,1]],"date-time":"1997-05-01T00:00:00Z","timestamp":862444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumori"],"published-print":{"date-parts":[[1997,5]]},"abstract":"<jats:sec>\n                    <jats:title>Aims and background<\/jats:title>\n                    <jats:p>There is evidence that fluorouracil (FU), when administered by protracted venous infusion, has antitumor activity in pretreated breast cancer. The aims of the study were to assess, in a population of heavily pretreated breast cancer patients (\u22652 lines of chemotherapy previously administered), the feasibility and activity of a new combination of oral L-leucovorin and continuous FU infusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients were treated with the following combination: oral L-leucovorin, 5 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      days 1 through 14, plus FU, 250 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      days 1 through 14, with cycles repeated every 21 days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Since November 1994, 22 patients have entered the study and 20 are assessable for response and side effects. Major patient characteristics were: ECOG performance status, 0-2; median age, 56 years (range, 41\u201370); sites of metastasis, bone 9, lung 8, liver 2, pleura 7; 2 or more metastatic sites, 18. A total of 74 cycles has been administered (median\/patient, 3 cycles). Five partial remissions (25%), 4 disease stabilizations and 11 disease progressions have been observed. Median time to progression was 3 months (range 1\u20136+). Grade I\u2013II mucositis was observed in 8 patients and grade III\u2013IV in 6 patients. Other side effects have included diarrhea and thrombocytopenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The schedule has demonstrated moderate activity in heavily pretreated breast cancer, with mucositis as the dose-limiting toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/030089169708300308","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T05:33:42Z","timestamp":1523943222000},"page":"665-668","source":"Crossref","is-referenced-by-count":0,"title":["Intermittent Continuous Infusion of Fluorouracil and Low-Dose Oral Leucovorin in Pretreated Breast Cancer: A Pilot Study"],"prefix":"10.1177","volume":"83","author":[{"given":"Marco","family":"Colleoni","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, City Hospital, Castelfranco Veneto, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Vicario","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, City Hospital, Castelfranco Veneto, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Nelli","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, City Hospital, Castelfranco Veneto, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gigliola","family":"Sgarbossa","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, City Hospital, Castelfranco Veneto, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Pancheri","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, City Hospital, Castelfranco Veneto, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Manente","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, City Hospital, Castelfranco Veneto, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1997,5,1]]},"reference":[{"key":"bibr1-030089169708300308","first-page":"111","volume":"3","author":"Anderson N.R.","year":"1993","journal-title":"J. Infusional Chemother."},{"key":"bibr2-030089169708300308","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058656"},{"key":"bibr3-030089169708300308","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(90)90128-G"},{"key":"bibr4-030089169708300308","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010573"},{"key":"bibr5-030089169708300308","doi-asserted-by":"publisher","DOI":"10.3109\/07357909109039875"},{"key":"bibr6-030089169708300308","first-page":"125","volume-title":"Important advances in oncology","author":"Hryniuk W.M.","year":"1988"},{"key":"bibr7-030089169708300308","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890201)63:3<419::AID-CNCR2820630303>3.0.CO;2-Z"},{"key":"bibr8-030089169708300308","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1259"},{"key":"bibr9-030089169708300308","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198302000-00017"},{"key":"bibr10-030089169708300308","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199404000-00018"},{"key":"bibr11-030089169708300308","doi-asserted-by":"publisher","DOI":"10.1159\/000226507"},{"key":"bibr12-030089169708300308","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00217-7"},{"key":"bibr13-030089169708300308","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.2.424"},{"key":"bibr14-030089169708300308","first-page":"3114","volume":"44","author":"Straw J.A.","year":"1984","journal-title":"Cancer Res."},{"key":"bibr15-030089169708300308","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19821001)50:7<1235::AID-CNCR2820500703>3.0.CO;2-L"},{"key":"bibr16-030089169708300308","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010478"},{"key":"bibr17-030089169708300308","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/4.suppl_2.S41"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089169708300308","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089169708300308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:45:04Z","timestamp":1777661104000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/030089169708300308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,5]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,5]]}},"alternative-id":["10.1177\/030089169708300308"],"URL":"https:\/\/doi.org\/10.1177\/030089169708300308","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,5]]}}}